Trial Profile
Phase I Study of Dual Immune Checkpoint Blockade (Anti-PD-L1 (Durvalumab) (MEDI4736) and Anti-CTLA4 (Tremelimumab) Plus Yttrium-90 (Y-90) Radioembolization & Stereotactic Body Radiation Therapy (SBRT) in Refractory Metastatic MSS (Microsatellite Stable) Colorectal Cancer With Liver Metastases
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Yttrium-90 (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions
- 20 Jun 2019 Planned initiation date changed from 1 May 2019 to 1 Aug 2019.
- 26 Apr 2019 Planned initiation date changed from 1 Mar 2019 to 1 May 2019.
- 21 Jan 2019 New trial record